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Chronic graft-versus-host disease (cGVHD) is a signiﬁcant determinant of overall outcome and quality of life
in survivors of allogeneic hematopoietic cell transplantation. Standard initial therapy of cGVHD is based on
prolonged use of corticosteroids and a calcineurin inhibitor and has not changed for over 3 decades, despite
limited efﬁcacy and long-term toxicity. Rituximab is an attractive agent for the upfront treatment of cGVHD
because of its favorable toxicity proﬁle, efﬁcacy in steroid-refractory cGVHD, and ability to serve as a steroid-
sparing agent in autoimmune diseases. We hypothesized that a corticosteroid-free regimen incorporating
rituximab would result in improved outcomes when used for the initial treatment of cGVHD. Twenty-ﬁve
patients (median age, 56 years; range, 29 to 77) with extensive cGVHD were enrolled on a prospective
phase II trial. Enrollment was limited to patients with ﬁrst onset extensive cGVHD requiring systemic
immunosuppression and without residual or concurrent acute graft-versus-host disease. cGVHD was clas-
siﬁed as de novo, interrupted, and progressive in 12, 11, and 2 patients, respectively. cGVHD severity (National
Institutes of Health grade) was mild, moderate, and severe in 3, 14, and 8 patients, respectively. All patients
received rituximab 375 mg/m2  4 weekly doses, then 1 dose every 3 months  4 doses, in addition to
mycophenolate mofetil and either tacrolimus or sirolimus. No other systemic immunosuppression was
permitted, and only a short-course of steroids (4 weeks) was allowed at physician discretion; otherwise,
treatment was deemed a failure and patients were treated off study. Twenty-two of 25 patients (88%)
responded to treatment. Of the 22 responding patients, the median time to maximum response was 161 days
(range, 35 to 300 days) with maximum response being complete in 21 of 22 patients and partial in 1 patient.
Excluding the 3 patients taken off study for treatment failure, corticosteroids were used sparingly, with only 2
patients receiving any steroids for a median of 15 days (range, 13 to 18 days). Immunosuppression was dis-
continued in 17 of 22 evaluable patients (77%) with a median time to discontinuation of 300 days (range, 138
to 488 days). After immunosuppression discontinuation, cGVHD did recur in 7 patients after a median of 166
days (range, 21 to 393 days), requiring reinstitution of systemic immunosuppression (estimated cGVHD
recurrence rate of 37%). With a median follow-up of 27 months, estimated 2-year overall survival is 82%. This
regimen utilizing rituximab in the initial therapy of cGVHD is effective and avoids the use of corticosteroids in
the majority of patients. In permitting early discontinuation of immunosuppression while obviating the need
for prolonged exposure to systemic corticosteroids, this regimen may result in reduced treatment-related
morbidity and mortality associated with cGVHD and its treatment.
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stem cells and mismatched and unrelated donors, and with
the increasing age of transplantation recipients, cGVHD will
continue to be a serious challenge after allogeneic trans-
plantation. cGVHD requires therapy for many months and
often years [5,6], and it is the cause of death in up to one third
of all long-term survivors after transplantation for leukemia
[7]. Moderate-to-severe cGVHD markedly reduces quality of
life, in addition to its effects on mortality [8-11]. Despite the
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effective treatment strategy for cGVHD has been difﬁcult to
achieve because of the heterogeneous nature of the problem
and the lack of clear evidence for the majority of treatment
options.
Standard immunosuppressive therapy (IST) for cGVHD
using glucocorticoids with a calcineurin inhibitor has not
changed in several decades, despite the fact that most pa-
tients respond inadequately. If the total time to discontinue
all systemic IST is measured as a surrogate for graft tolerance,
it takes a median of 2 to 3 years from the onset of cGVHD
therapy, depending on stem cell source and other factors
[12]. Unfortunately, despite the relationship between cGVHD
and reduced relapse risk, the prolonged duration of cGVHD
makes it the leading cause of infection, morbidity, and late
treatment-related deaths [8,13-17]. The widespread and
sometimes irreversible manifestations of cGVHD may nega-
tively impact quality of life, even after tolerance is achieved.
New approaches to the treatment of cGVHD are needed to
achieve early control of cGVHD manifestations and facilitate
tolerance.
The morbidity and mortality associated with cGVHD are
caused not only by cGVHD-associated immunodeﬁciency and
organ dysfunction, but also by the immunosuppressive
medications used treat it. Long-term glucocorticoid treat-
ment impairs immune function and can, therefore, increase
the risk of opportunistic infections. Other glucocorticoid
therapy-related complications include avascular necrosis,
glucose intolerance, hypertension, weight gain, changes in
body habitus, cataracts, osteoporosis, myopathy, and distur-
bances of mood and sleep. Attempts to improve upon corti-
costeroids and a calcineurin inhibitor as initial therapy for
cGVHD have been unsuccessful.
Failure to improve cGVHD therapy may be partly attrib-
uted to an incomplete understanding of the pathophysiology
of cGVHD. cGVHD is traditionally thought to be mediated by
donor-derived, alloreactive T cells, although studies have not
consistently shown a favorable impact of T cell depletion on
cGVHD [18,19]. There is now mounting evidence implicating
B cells in the pathophysiology of cGVHD. Antibodies to Y
chromosomeeencoded minor histocompatibility antigens
are generated after sex-mismatched allogeneic trans-
plantation [20] and the presence of these antibodies has
been correlated with the occurrence of cGVHD [21]. These
ﬁndings led to the hypothesis that an antieB cell monoclonal
antibody may be an effective therapy for cGVHD. Clinical
studies have subsequently conﬁrmed the efﬁcacy of ritux-
imab in steroid-refractory cGVHD, with objective responses
noted in 50% to 70% of patients, allowing tapering and, in
some cases, withdrawal of IST [22-26]. Early evidence also
suggests a role for rituximab during the early post-
transplantation period for prevention of cGVHD [27,28].
In the current study, we hypothesized that rituximab
would be efﬁcacious in the upfront treatment of patients
with extensive cGVHD. Incorporation of rituximab into the
initial treatment of cGVHD may be advantageous because of
its favorable toxicity proﬁle, its proven efﬁcacy in the treat-
ment of steroid-refractory cGVHD, and its ability to serve as a
steroid-sparing agent in other autoimmune diseases [29-34].
We hoped to demonstrate that rituximab would have sig-
niﬁcant activity in the initial therapy of cGVHD while elim-
inating the need for corticosteroids. In addition, we
hypothesized that the early use of rituximab would allow for
earlier discontinuation of IST, which should translate into
reduced treatment-related morbidity and mortality.PATIENTS AND METHODS
Eligibility and Enrollment
Eligible patients were those with a ﬁrst episode of symptomatic
extensive cGVHD, requiring systemic immunosuppression. The diagnosis of
cGVHD was made by National Institutes of Health (NIH) consensus criteria
[35], requiring, at a minimum, the presence of at least 1 diagnostic clinical
sign of cGVHD or the presence of at least 1 distinctive clinical manifestation
conﬁrmed by biopsy or other relevant tests in the same or another organ.
Patients were excluded from the study based on the following criteria:
creatinine > 2.0 mg/dL, uncontrolled infection, recurrent or progressive
malignancy, residual or concurrent acute graft-versus-host disease (GVHD),
systemic corticosteroid use > 7 days before study initiation, or minimally
symptomatic cGVHD requiring local therapy only.
Treatment Plan
Patients were initiated on a corticosteroid-free treatment regimen
consisting of rituximab. A 375 mg/m2 dose was administered for 4 weekly
doses on day 1, 8, 15, and 22, then 1 dose every 3 months  4 doses (3, 6, 9,
and 12months after study initiation). Tacrolimus was continued/resumed to
maintain serum levels of 10 to 20 ng/mL (sirolimus could be substituted if
there were a contraindication/intolerance to tacrolimus). Mycophenolate
mofetil was started at a dose of 15 mg/kg twice daily. All other immuno-
suppressive agents, excluding locally acting corticosteroids or other topical
agents, were not permitted.When cGVHDwas inactive/quiescent for at least
4 weeks, immunosuppressive drugs were tapered at the discretion of the
treating physician. Systemic corticosteroids could be added to the regimen,
at the discretion of the treating physician, if cGVHD progressed after 2 weeks
of therapy or showed no improvement after 4 weeks of therapy. If a patient
then responded to systemic corticosteroids, they were subsequently tapered
so as to be discontinued by 4weeks. Patients requiring>4weeks of systemic
corticosteroids and/or additional immunosuppressive medications/in-
terventions were considered to have treatment failures, and further treat-
ment was performed off-study at the discretion of the treating physician.
Study Assessments
Formal study assessments were performed at 1, 2, 3, 6, 9, 12, 18, and 24
months, and included medical history, physical examination, laboratory
evaluation, documentation of concomitant medications, completion of
institutional GVHD assessment form, and completion of a GVHD patient self-
report form. All patients, responders, and those with treatment failure had
planned follow-up for a period of 2 years.
Study Endpoints
The primary objective of the study was to estimate the rate of complete
and overall response of cGVHD to treatment. Complete response (CR) was
deﬁned as resolution of all reversible manifestations of cGVHD. Partial
responsewas deﬁned as improvement in global NIH severity grade (eg, from
severe to moderate, frommoderate to mild, etc). Secondary objectives were
to estimate the requirement for and duration of systemic corticosteroids;
time to immunosuppression withdrawal; and incidence of nonrelapse
mortality (NRM), disease-free and overall survival, cGVHD recurrence after
IST discontinuation, and need for second-line cGVHD therapy. Second-line
cGVHD therapy was deﬁned as requirement for corticosteroids > 4 weeks,
additional nonstudy therapeutic agents, or extracorporeal photopheresis.
This was distinguished from the reinstitution of study drugs after IST
withdrawal for cGVHD recurrence, which was not considered second-line
cGVHD therapy.
Statistical Analysis
The study was powered to detect a statistically signiﬁcant increase in
cGVHD CR rate when compared with historical results in patients treated
with systemic corticosteroids and a calcineurin inhibitor (approximately
50%) [36,37]. It was hypothesized that, under this protocol, the ratewould be
at least 80%. Thus, we statistically formalized this study by testing the null
hypothesis that P, the CR rate, is .5 or less versus the alternative hypothesis
that P is greater than .5. A sample size of 25 patients gives 90% powerwith an
alpha ¼ .05, using the formula for a 1-sample binomial (2-sided) test of a
proportion.
The Kaplan-Meier method was used to estimate the survival probabil-
ities. The cumulative incidence was estimated for NRM, relapse, require-
ment of second-line treatment, and cGVHD recurrence to accommodate
competing risk. NRM and relapse were competing risks for each other and
were both competing risks for requirement of second-line treatment. The
competing risk of cGVHD recurrence was non-cGVHD death. The start of the
initial immunosuppression was considered as the time origin for all end-
points except for cGVHD recurrence, for which achievement of complete
response was the time origin.
Table 2
Chronic GVHD Characteristics
Characteristic Value
Patients (n ¼ 25)
Post-transplantation day, median (range) 250 (152-545)
cGVHD classiﬁcation
De novo 12
Interrupted 11
Progressive 2
NIH cGVHD severity
Mild 3
Moderate 14
Severe 8
NIH symptom score, median (range) 5 (4-9)
Organ involvement, median no. (range) 3 (2-6)
Organ involvement, no. affected organ (%)
Oral 24 (96%)
Cutaneous 14 (56%)
Gastrointestinal 12 (48%)
Ocular 10 (40%)
Hepatic 8 (32%)
Genital 5 (20%)
Pulmonary 2 (8%)
Musculoskeletal 1 (4%)
Data presented are n, unless otherwise indicated.
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Characteristics of the Study Cohort
BetweenMay 2011 and January 2014, 25 participants with
symptomatic extensive cGVHD were enrolled. All patients
received rituximab per protocol in addition to mycopheno-
late mofetil. Eighteen patients (72%) received tacrolimus and
the remaining 7 patients received sirolimus. Patient charac-
teristics are summarized in Table 1. The median age of pa-
tients was 56 years (range, 29 to 77 years). Twelve patients
(48%) received myeloablative conditioning and 22 (88%)
received mobilized peripheral blood cell grafts. cGVHD
characteristics at study entry are summarized in Table 2. The
median time from transplantation to initial systemic treat-
ment of cGVHD was 8 months (range, 4 to 18 months). The
median number of sites involved by cGVHDwas 3 (range, 2 to
6). The sites most frequently involved at the onset of initial
systemic treatment were the mouth (96%) and skin (56%),
followed by the gut (48%), eyes (40%), and liver (32%). cGVHD
was classiﬁed as de novo, interrupted, and progressive in
48%, 44%, and 8% of patients respectively. NIH cGVHD
severity was mild, moderate, and severe in 12%, 56%, and 32%
of patients respectively. Median NIH symptom score at study
onset was 5 (range, 4 to 9). Seventeen patients (68%) hadTable 1
Patient and Transplantation Characteristics
Characteristic Value
No. of patients 25
Age, median (range) 56 (29-77)
Sex (m/f) 12/13
KPS < 80 6
Disease
AML 11
ALL 2
MDS 7
NHL 3
CLL 1
HD 1
Disease risk index
Low 3
Intermediate 17
High 4
Very high 1
Stem cell source
BM 3
PBSC 22
Donor type
MSD 13
MUD 9
HAPLO 3
Conditioning intensity
MA 12
RIC 9
NMA 4
GVHD prophylaxis
Tac/Mtx 19
CSA/MMF 1
PTCy/Tac/MMF 3
PTCy/sirolimus 2
Acute GVHD
Grade 1-2 13
Grade 3-4 0
M indicates male; F, female; KPS, Karnofsky performance status; AML, acute
myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelo-
dysplastic syndrome; NHL, non-Hodgkin lymphoma; CLL, chronic lympho-
cytic leukemia; HD, Hodgkin’s disease; BM, bone marrow; PBSC, peripheral
blood stem cells; MSD, matched sibling donor; MUD, matched unrelated
donor; HAPLO, haploidentical donor; MA, myeloablative conditioning; RIC,
reduced-intensity conditioning; NMA, nonmyeloablative conditioning; Tac,
tacrolimus; Mtx, methotrexate; CSA, cyclosporine A; MMF, mycophenolate
mofetil; PTCy, post-transplantation cyclophosphamide.involvement of3 sites, 6 (24%) had a Karnofsky score< 80%,
and 6 (24%) had thrombocytopenia. The median follow-up
among survivors was 29 months (range, 12 to 44 months)
from initial treatment on study.Toxicity and Infection
Study therapy was well tolerated and there were no un-
expected severe adverse events. Hypogammaglobulinemia
occurred in 17 (68%) patients, requiring intravenous immu-
noglobulin replacement therapy. There were no cases of
avascular necrosis. Cytomegalovirus (CMV) reactivation
occurred in 4 (22%) of 18 at-risk patients. This included 2
cases of CMV enteritis and 1 case of CMV pneumonitis (1 case
in patient receiving second-line cGVHD therapy). There were
3 cases (12%) of invasive fungal infection (2 of these cases in
patients receiving second-line cGVHD treatment including
corticosteroids). There were no occurrences of Epstein-Barr
virus reactivation.Clinical Response
Twenty-two of 25 patients (88%) responded to treatment,
2 patients were deemed to have treatment failures and
proceeded to second-line treatment, and 1 patient died early
of GVHD-related mortality and was, thus, nonevaluable. The
2 patients with treatment failures included 1 patient
removed from study after 2 months for progressive bron-
chiolitis obliterans syndrome and a second patient removed
from study after 4 months for progressive esophageal
involvement. Of the 22 responding patients, median time to
maximum response was 161 days (range, 35 to 300 days)
with maximum response being CR in 21 of 22 patients and
partial response in 1 patient deﬁned by improvement in
severity grade (overall and CR rates were 88% and 84%,
respectively). A third patient was deemed to have treatment
failure at 12 months after transplantation for progressive
bronchiolitis obliterans syndrome that occurred after reso-
lution of GVHD and 4 months after discontinuation of
immunosuppression.
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Excluding the 3 patients taken off study for treatment
failure, corticosteroids were used sparingly, with only 2 pa-
tients receiving any steroids, for a median of 15 days (range,
13 to 18 days). In total, 20 of 25 patients (80%) received no
corticosteroids at all during the course of treatment for
cGVHD. Immunosuppression was ultimately discontinued in
17 of 22 evaluable patients (77%) who initially responded to
study therapy, with a median time to immunosuppression
discontinuation of 300 days (range, 138 to 488 days). The
estimated probabilities of remaining on immunosuppression
at 12 and 24months after initial GVHD therapy were 36% and
23%, respectively. The clinical course of each patient is
graphically depicted in Figure 1.Failure-free and Overall Survival
With a median follow-up of 27 months (range, 11 to 44
months) for surviving patients, the estimated 2-year overall
survival is 82% (Figure 2A). Of the survivingpatients at 2 years,
79%areestimated tobe freeof activeGVHD,whereas77%have
discontinued systemic immunosuppression. The 2-year in-
cidencesof disease relapse,NRM(Figure2B), and requirement
for second-line cGVHD therapy were 9%, 21%, and 12%,
respectively. Failure-free survival (FFS), deﬁnedby the absence
of second-line treatment, relapse, or NRM, was estimated to
be 80% and 67%, at 1 and 2 years, respectively (Figure 2C).cGVHD Recurrence
After immunosuppression discontinuation, cGVHD
recurred in 7 patients after a median of 166 days (range, 21 to
393 days), requiring reinstitution of systemic immunosup-
pression. The estimated incidences of GVHD recurrence at 12
and 24 months after GVHD resolution were 20% and 37%,
respectively (Figure 3).Figure 1. Clinical course of the 25DISCUSSION
This study demonstrates that this rituximab-based,
corticosteroid-free regimen has signiﬁcant activity in
cGVHD when used for initial therapy. The results of this
study challenge the long-held dogma that corticosteroids are
required for the initial treatment of symptomatic cGVHD.
Despite the fact that the majority of our patients received no
corticosteroids at all, 22 of 25 patients (88%) responded to
treatment, with maximum response being complete in 21 on
them (84%). Immunosuppression was ultimately dis-
continued in 17 of 22 evaluable patients (77%) with median
time to immunosuppression discontinuation of 300 days
(range, 138 to 488 days). Rituximab-based therapy of cGVHD
was well tolerated and was associated with low treatment-
related morbidity and mortality and an excellent 2-year
overall survival of 82%. However, GVHD relapse remains a
concern with slightly over one third of patients predicted to
recur with GVHD requiring reinstitution of systemic
immunosuppression.
The morbidity and mortality associated with cGVHD are
caused both by cGVHD-associated immunodeﬁciency and
organ dysfunction and by the immunosuppressive medica-
tions used treat it. High-dose corticosteroids and continued
administration of a calcineurin inhibitor have long served as
the mainstay of treatment for cGVHD. Randomized trials
have evaluated the addition of other agents (azathioprine,
cyclosporine, thalidomide, mycophenolate mofetil, hydrox-
ychloroquine) to prednisone for the initial treatment of
cGVHD [15,36,38-40]. Of these, only the addition of cyclo-
sporine demonstrated a potential clinical beneﬁt by
decreasing prednisone exposure.
The median duration of treatment for cGVHD is approx-
imately 2 years in patients receiving an allogeneic marrow
transplant and approximately 3.5 years in those who un-
dergo transplantation with peripheral blood stem cells [41].
In a subset of patients, treatment is prolonged, with 15% still
receiving IST 7 or more years after the initial diagnosis ofsubjects enrolled on study.
Figure 2. Kaplan-Meier analysis of (top) overall survival, (middle) failure-free
survival, and (bottom) nonrelapse mortality.
Figure 3. Cumulative incidence of cGVHD recurrence in patients who have
previously achieved a complete response to therapy.
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immune function and can, therefore, increase the risk of
opportunistic infections. Patients may also experience other
corticosteroid-related complications, including avascular
necrosis, glucose intolerance, hypertension, weight gain,
changes in body habitus, cataracts, osteoporosis, myopathy,
and disturbances of mood and sleep. Development of less
toxic treatments that could reduce the dose or duration of
corticosteroid administration or improve disease control
would be of signiﬁcant beneﬁt to patients with cGVHD.
Comparison of our results with historical data is
complicated by the more recent introduction of the NIH
consensus criteria [35], introduced in 2005, which deﬁned
cGVHD by clinical characteristics rather than the timing of
GVHD. Using these new criteria, approximately 15% to 37%
of patients previously classiﬁed as having cGVHD are nowconsidered to have late onset, persistent, or recurrent acute
GVHD [42-45]. However, despite the inherent limitations of
comparing results to historical data, some lessons may still
be drawn (Table 3). First, corticosteroid-free therapy with
rituximab appears to produce similar response rates to
those reported for standard corticosteroid-based treatment
(overall response in current study is 88% versus 79% to 90%
[36,37]). Furthermore, CR rates appear at least as good as
and perhaps superior to those reported with standard
therapy (84% versus 52% to 58% [36,37]). Faster withdrawal
of immunosuppression appears feasible after rituximab-
based treatment, with 77% of patients being free of sys-
temic immunosuppression 2 years after treatment initiation
for cGVHD versus 13% to 28% with standard corticosteroid-
based therapy [12,37,40,41,46,47]. In a retrospective study
of 400 consecutive patients who received initial systemic
treatment of cGVHD at the Fred Hutchinson Cancer Center
[46], FFS was deﬁned by the absence of second-line treat-
ment, NRM, and recurrent malignancy during initial treat-
ment. The FFS rate was 54% 12 months after initial
treatment compared with a FFS rate of 80% 12 months in the
current study.
Although rituximab-based, corticosteroid-free therapy of
cGVHD appears to produce more CR and faster immuno-
suppression withdrawal, it is less clear whether the current
therapeutic approach accelerates the development of
immunological tolerance. Recurrence of cGVHD remains an
issue, with 37% of patients predicted to have recurrence of
their GVHD within 2 years of achieving a CR. This failure to
produce durable responses in a subset of cGVHD patients,
however, does not appear to be unique to rituximab-based
therapy, as similar cGVHD recurrence rates have been re-
ported after standard corticosteroid-based therapy (26% to
61% [37,48]) (Table 3). cGVHD recurrence rates have been
reported to be higher after peripheral blood stem cell versus
bone marrow transplantations (37% versus 5% [48]).
In patients with autoimmune diseases, initial responses
to rituximab are followed by recurrence in most patients.
Because increased plasma B celleactivating factor (BAFF)
levels are found in patients with autoimmune disease after
rituximab treatment, it has been hypothesized that high
BAFF levels contribute to clinical relapse through inefﬁcient
elimination of autoreactive B cells [49-52]. Elevated levels of
BAFF have been correlated with the development and
severity of cGVHD [53-55]. As survival signals delivered by
BAFF may protect autoreactive and alloreactive B cells from
Table 3
Comparison of Outcomes with Historical Experience
Study n Age,
median
PBSC MSD NIH
Severe
Progressive
Onset
KPS < 80 CR CR þ PR Twelve-
Month FFS*
Twenty-four-
Month IST
W/D
cGVHD
Relapsey
Overall
Survival
NRM
Current study 25 56 88% 52% 32% 8% 24% 84% 88% 80% 77% 37% 73% at 2 yr 21%
Inamoto et al.
Blood 2014
400 52 83% 37% 43% 10% 35% e e 54% 13% e e 12%
Martin et al.
BBMT 2011
116 e e e e e e e e e 25% e e e
Martin et al.
Blood 2009
151 e 84% 51% 7% 10% 21% e e e 20% e e e
Perez-Simon et al.
BBMT 2008
171 45 100% 100% 28% 8% e 58% 90% e w28% 61% e 13%
Jagasia et al.
BBMT 2007
73 42 64% 82% 22% e e e e e e e 68% at 3 yr 21%
Stewart et al.
Blood 2004
751 40 20% 44% e 14% e e e e w25% e e 22%
Flowers et al.
Blood 2002
71 44 55% 100% e 13% e e e e 20% e 73% at 3 yr e
Mohty et al.
Blood 2002
50 e 62% e e 44% e e e e e 26% all 39%
PBSC
e e
Arora et al.
BBMT 2001
54 41 e 63% e 17% e 52% 79% e e e e e
PR indicates partial response; W/D, withdrawal.
* FFS deﬁned by the absence of second-line treatment, nonrelapse mortality, or recurrent malignancy.
y cGVHD relapse indicates risk of recurrence of chronic graft-versus-host disease after resolution of cGVHD.
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one explanation for the failure of rituximab to produce graft
tolerance in a subset of patients. It may also serve as a
rationale for combined therapy consisting of rituximab and a
BAFF inhibitor, which may provide synergistic effects and
perhaps enhanced efﬁcacy.
Evidence from clinical studies of rituximab in autoim-
munity also suggests that rituximab may be more effective
when given early in the disease [56-60], before establish-
ment of B and T cell abnormalities, which may be less
amenable to treatment [61]. In addition to B cell depletion,
treatment with rituximab has widespread effects on the
immune system, including downregulation of important
costimulatory molecules such as CD40 and CD80 [62],
upregulation of regulatory T cell number and function [63],
reversal of some of the disturbances of the peripheral B cell
pool, and reconstitution of normal B and T cell homeostasis
in patients with autoimmune disease [29].
In conclusion, rituximab-based, corticosteroid-free
treatment has signiﬁcant activity in extensive cGVHD when
utilized for initial therapy. It obviates the need for prolonged
courses of systemic corticosteroids while permitting earlier
discontinuation of immunosuppression, which may result in
reduced treatment-related morbidity and mortality associ-
ated with cGVHD and its treatment. Prevention of GVHD
recurrence remains an important issue, and future studies
evaluating higher-potency second/third-generation anti-
CD20 monoclonal antibodies, as well as combinations with
BAFF inhibition, are needed.
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